Mitomycin and Second primary malignancy - a phase IV clinical study of FDA data

Summary:

Second primary malignancy is reported as a side effect among people who take Mitomycin (mitomycin), especially for people who are female, 60+ old, also take Cyclophosphamide, and have Breast cancer.

The phase IV clinical study analyzes which people have Second primary malignancy when taking Mitomycin. It is created by eHealthMe based on reports of 4,183 people who have side effects when taking Mitomycin from the FDA, and is updated regularly.

What is Mitomycin?

Mitomycin has active ingredients of mitomycin. eHealthMe is studying from 4,195 Mitomycin users. Check the latest studies of Mitomycin.

What is Second primary malignancy?

Second primary malignancy (after getting cure a cancer, a new cancer development) is found to be associated with 542 drugs and 464 conditions by eHealthMe. Check the latest studies of Second primary malignancy.

On Apr, 26, 2026

4,183 people reported to have side effects when taking Mitomycin.
Among them, 15 people (0.36%) have Second primary malignancy.

Could Mitomycin cause Second primary malignancy?

Among these 15 people:

What is the gender of people who have Second primary malignancy when taking Mitomycin? *

female: 86.67 %
male: 13.33 %

What is the age of people who have Second primary malignancy when taking Mitomycin? *

What are other drugs people take besides Mitomycin? *

Vincristine Sulfate: 2 people, 13.33%
Fluorouracil: 2 people, 13.33%
Etoposide: 2 people, 13.33%
Cyclophosphamide: 2 people, 13.33%

What are other side effects people have besides Second primary malignancy? *

Acute Promyelocytic Leukaemia (cancer of the blood and bone marrow): 12 people, 80.00%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 2 people, 13.33%
Central Nervous System Haemorrhage (bleeding in brain and surrounding): 1 person, 6.67%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 1 person, 6.67%

What are the existing conditions these people have? *

Breast Cancer: 7 people, 46.67%
Benign Breast Neoplasm (benign (non-cancerous) tumours of the breast): 6 people, 40.00%
Ovarian Cancer (cancer of ovary): 4 people, 26.67%
Lung Cancer - Small Cell (lung cancer): 1 person, 6.67%
Acute Promyelocytic Leukaemia (cancer of the blood and bone marrow): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Mitomycin and have Second primary malignancy?

- Check whether Second primary malignancy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Mitomycin:

Mitomycin (4,195 reports)

Browse all side effects of Mitomycin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Second primary malignancy:

Second primary malignancy (542 drugs)

Browse all the conditions that are associated with Second primary malignancy:

Second primary malignancy (464 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on mitomycin (the active ingredients of Mitomycin) and Mitomycin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.